SH2D5 has been documented to be up-regulated in liver tissues of HBV-HCC patients as compared to adjacent non-tumor tissues, and gain- and loss-of-function experiments have substantiated that elevation of SH2D5 expedites liver cancer cell proliferation in vitro and in vivo, and patients with high SH2D5 RNA levels have shorter OS (Zheng et al., 2019). The gene discussed is SH2D5; the disease is liver cancer.